Showing 5981-5990 of 7934 results for "".
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac
- FDA Approves Humira Biosimilar Hyrimozhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar-hyrimoz/2461636/The FDA approved a citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz; Sandoz) injection, a biosimilar to Humira (adalimumab). The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira, in
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was
- New North Carolina Courage Jerseys to Feature Merz Aesthetics Sponsorshiphttps://practicaldermatology.com/news/new-north-carolina-courage-jerseys-to-feature-merz-aesthetics-sponsorship-1/2461632/Merz Aesthetics North America has launched its front-of-jersey sponsorship deal with the
- Take That SKs! DermBiont’s SM-020 Topical Gel Performs Well in Phase 2 Studyhttps://practicaldermatology.com/news/take-that-sks-dermbionts-sm-020-topical-gel-performs-well-in-phase-2-study/2461623/More than 80% of seborrheic keratosis (SK) lesions treated for 14 to 28 days with DermBiont’s SM-020 gel 1.0% had at least a one-point improvement in Physician’s lesion assessment (PLA) score at last visit, according to Phase 2 trial data presented at the
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t
- Eye on OX40 in AD: Rocatinlimab Performs Well in Two Phase 2 Trialshttps://practicaldermatology.com/news/eye-on-ox40-in-ad-rocatinlimab-performs-well-in-two-phase-2-trials/2461617/OX40 is considered a new potential treatment target in atopic dermatitis (AD), and two new studies of the investigational anti-OX40 monoclonal antibody rocatinlimab may add weight to the evidence. Rocatinlimab inhibits and reduces the number of OX40+ pathogenic T cells responsible
- AbbVie Enters Doc Film Biz: Company Releases New Film on Life with Eczemahttps://practicaldermatology.com/news/abbvie-enters-doc-film-biz-company-releases-new-film-on-living-with-eczema/2461609/AbbVie is releasing a new documentary film, “Under My Skin: Untold Stories of Life with Eczema,” which debuted at South by Southwest 2023 in Austin, Texas. The film, directed by Redglass Pictures, features the physical and emotional stories of three ind
- Health Canada Approves Candela's Picoway for Melasmahttps://practicaldermatology.com/news/health-canada-approves-candelas-picoway-for-melasma/2461608/Health Canada has granted Candela’s PicoWay laser system licensing for expanded indications, including the melasma, lentigines, café au lait macules (CALMs), and Nevus of Ota. The US Food and Drug Administration gave the device a similar same nod in Oct
- AI Model Helps AD Patients Diagnose Complications, Cancerhttps://practicaldermatology.com/news/ai-model-helps-ad-patients-diagnose-complications-cancer/2461606/A new artificial intelligence (AI) model can empower atopic dermatitis (AD) patients to detect complications from bacterial or viral infections and distinguish between eczema and skin lesions caused by mycosis fungoides. The AI model is detailed in a paper published in the